Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE® in Canada for Opioid Drug Dependence

Braeburn Pharmaceuticals, Inc. (“Braeburn”) and Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company has announced that Knight’s New Drug Submission (NDS) has been accepted for review by Health Canada for PROBUPHINE® (buprenorphine subdermal implant) for the treatment of opioid drug dependence.

“Probuphine is a unique and innovative product that has the potential to address an important unmet need for opioid dependent patients,” said Jonathan Ross Goodman, Chief Executive Officer of Knight. “With Probuphine, Knight is continuing to advance its portfolio of opioid supportive therapeutics, which includes Movantik®, a product for opioid-induced constipation we in-licensed from AstraZeneca and began commercializing in March of this year.”

“Opioid addiction is an overwhelming public health epidemic in North America. This is another important milestone for Probuphine, an innovative treatment approach with the potential to reduce the risks of diversion, abuse and accidental pediatric exposure,” said Mike Derkacz, President and CEO of Braeburn. “We look forward to working with Knight and Health Canada to bring this important treatment option to Canadian patients.”

Knight and Braeburn signed an exclusive distribution and sublicense agreement in February 2016 granting Knight the exclusive right to distribute Probuphine in Canada.


The Canadian Business Quarterly (The CBQ) provides an in-depth view of business and economic development issues taking place across the country. Featuring interviews with top executives, government policy makers and prominent industry bodies The CBQ examines the news beyond the headlines to uncover the drivers of local, provincial, and national affairs.

All copy appearing in The Canadian Business Quarterly is copyrighted. Reproduction in whole or part is not permitted without written permission. Any financial advice published in The Canadian Business Quarterly or on has been prepared without taking in to account the objectives, financial situation or needs of any reader. Neither The Canadian Business Quarterly nor the publisher nor any of its employees hold any responsibility for any losses and or injury incurred (if any) by acting on information provided in this magazine or website. All opinions expressed are held solely by the contributors and are not endorsed by The Canadian Business Quarterly or

All reasonable care is taken to ensure truth and accuracy, but neither the editor nor the publisher can be held responsible for errors or omissions in articles, advertising, photographs or illustrations. Unsolicited manuscripts are welcome but cannot be returned without a stamped, self-addressed envelope. The publisher is not responsible for material submitted for consideration. The CBQ is published by Romulus Rising Pty Ltd, ABN: 77 601 723 111.


© 2023 The Canadian Business Quarterly. All rights reserved. A division of Romulus Rising Pty Ltd, an Australian media company (